Sugi Predict

Sugi Predict / Compounds / SCHEMBL1401802

SCHEMBL1401802

SCHEMBL1401802

N#CCc1cc(COc2ccccc2)c(F)cc1[N+](=O)[O-]

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ PTGES O14684 3/20 0.47
▸ MAOB P27338 1/20 0.40
▸ NPC1 O15118 3/20 0.37
▸ RAB9A P51151 3/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ AR P10275 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ FFAR1 O14842 1/20 0.35
▸ TSPO P30536 1/20 0.35
▸ DRD3 P35462 1/20 0.35
▸ FFAR4 Q5NUL3 1/20 0.35
▸ KDM4A O75164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401807 0.80 ALDH1A1 (0.48) ALDH1A1HPGDPTGESMAPTMEN1
SCHEMBL1401674 0.78 ALDH1A1 (0.46) ALDH1A1HPGDPTGESMAOBNPC1
SCHEMBL8148611 0.77 ALDH1A1 (0.54) ALDH1A1HPGDRAB9ASMN1; SMN2MAPT
SCHEMBL8388636 0.75 ALDH1A1 (0.55) ALDH1A1HPGDPTGESMAOBNPC1
SCHEMBL29805068 0.73 ALDH1A1 (0.52) ALDH1A1HPGDNPC1RAB9AMAPT
SCHEMBL8967901 0.73 ALDH1A1 (0.52) ALDH1A1HPGDNPC1RAB9AMAPT
SCHEMBL7158569 0.72 PTGES (0.51) ALDH1A1PTGESMAOBNPC1RAB9A
SCHEMBL1401653 0.72 SMN1; SMN2 (0.48) ALDH1A1PTGESMAOBSMN1; SMN2MAPT
SCHEMBL26093121 0.72 PTGES (0.57) ALDH1A1PTGESMAOBNPC1RAB9A
SCHEMBL28464813 0.72 ALDH1A1 (0.49) ALDH1A1HPGDRAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 — — EP claimed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 — — US claimed
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 — — US disclosed
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 — — US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 — — US disclosed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 — — EP disclosed
EP-1553097-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE ASTRAZENECA AB (SE) 2010-09-29 — — EP disclosed
US-20090156821-A1 Quinazoline compounds ASTRAZENECA AB 2009-06-18 — — US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 — — EP disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 — — US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 — — EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 — — EP disclosed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 — — US disclosed
US-20030207878-A1 Chemical compounds ASTRAZENECA AB (SE) 2003-11-06 — — US disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 — — US disclosed
EP-1311500-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-21 — — EP disclosed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 ALDH1A1 1187/4885HPGD 1360/4885PTGES 1451/4885
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents VEGFA, FLT4, FLT1 ALDH1A1 1174/4885HPGD 2395/4885PTGES 1680/4885
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR ALDH1A1 822/4885HPGD 348/4885PTGES 696/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 ALDH1A1 2513/4885HPGD 1207/4885PTGES 977/4885
US-20090156821-A1 Quinazoline compounds VEGFA, FLT4, FLT1 ALDH1A1 1080/4885HPGD 2495/4885PTGES 2070/4885
US-20030207878-A1 Chemical compounds CYP3A7, HTR3C, CNR1 ALDH1A1 1354/4885HPGD 1253/4885PTGES 2577/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 ALDH1A1 3323/4885HPGD 1830/4885PTGES 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.